The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat?

Cancer Res Treat

Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France.

Published: November 2024

Antibody Drug Conjugates (ADCs) are a novel class of therapeutics that structurally are composed by an antibody directed to a tumour epitope connected via a linker to a cytotoxic payload, and that have shown significant antitumor activity across a range of malignancies including lung cancer. In this article we review the pharmacology and design of ADCs, as well as we describe the results of different studies evaluating ADCs in lung cancer directed to several targets including HER2, HER3, TROP2, MET, CEACAM5 and DLL3, among others.

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2024.714DOI Listing

Publication Analysis

Top Keywords

lung cancer
12
antibody drug
8
drug conjugates
8
era antibody
4
conjugates lung
4
cancer trick
4
trick threat?
4
threat? antibody
4
conjugates adcs
4
adcs novel
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!